Bio Pharma Dive

APRIL 3, 2023

The biotech is expanding its cancer medicine pipeline by licensing two experimental antibody drug conjugates from Shanghai-based Duality.

Licensing 297

Licensing Licensing Antibody Medicine 297

Pharmaceutical Technology

JUNE 20, 2023

The investigational drug candidate vamorolone has a mode of action based on binding to the same receptor as glucocorticoids while changing its downstream activity. In the US and Europe, the drug has received orphan drug status to treat Duchenne muscular dystrophy (DMD).

Licensing 246

Licensing Licensing Drugs Medicine 246

Bio Pharma Dive

JANUARY 9, 2025

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind Biosciences, led by an oral therapy ready for Phase 2 testing.

Licensing 256

Licensing Licensing Medicine Drugs 256

Drug Patent Watch

JULY 30, 2024

The Power of Patent Licensing: Unlocking Innovation and Access to Medicines Patent licensing agreements have become a crucial tool in the pharmaceutical industry, allowing companies to collaborate and…

Licensing 105

Licensing Licensing Drugs Medicine 105

Bio Pharma Dive

OCTOBER 9, 2024

The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.

Medicine 164

Medicine Licensing Licensing Development 164

AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 21, 2023

The Union Ministry of Ayush has submitted in the Delhi High Court that it has instructed the licensing authority for the Ayush systems of medicines in all the States and Union Territories that they should ensure that the labelling and naming of the products for the Ayurvedic and Unani drugs should be as per the […]

Regulation 188

Regulation Drugs Licensing Licensing 188

Pharmaceutical Technology

APRIL 3, 2023

Ablaze Pharmaceuticals is set to develop a new GPC3-targeted peptide drug candidate for the treatment of liver cancer in China. The company is licensing the first-in-class drug candidate under an existing deal with RayzeBio. The agreement allows Ablaze to clinically develop and commercialise the drug in Greater China.

Development 246

Development Drugs Clinical Development Licensing 246

Bio Pharma Dive

MAY 9, 2024

The deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi licensed from biotech ImmuNext and expects to be a future blockbuster.

Licensing 187

Licensing Licensing Medicine Drugs 187

STAT News

JANUARY 5, 2023

Last fall, Novartis agreed to license a best-selling cancer drug so that generic companies could make copies for distribution to 44 low- and middle-income nations, marking the first time a voluntary license was arranged for a cancer medicine. ANNECY, FRANCE — At first blush, the deal was hailed as a breakthrough.

Licensing 116

Licensing Licensing Medicine Drugs 116

Pharma Mirror

APRIL 18, 2023

Dudley, UK, April 18th 2023: Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).

Licensing 130

Licensing Licensing Manufacturing Antibody 130

Bio Pharma Dive

JUNE 21, 2024

A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.

Licensing 164

Licensing Licensing Development Antibody 164

pharmaphorum

JANUARY 25, 2024

Indian pharma Glenmark has licensed rights to subcutaneous PD-L1 inhibitor envafolimab from China’s Alphamab and 3D Medicines

Licensing 110

Licensing Licensing Medicine Drugs 110

Bio Pharma Dive

APRIL 23, 2024

Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.

Licensing 164

Licensing Licensing Drugs Medicine 164

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. As opposed to other therapies or drugs that basically help you manage a condition, gene therapy has the potential to cure a disease,” says Nicole Faust, PhD, General Manager, Cell Line Development, Cytiva. CEVEC became part of Cytiva in October 2022.

Genomics 244

Genomics Genome Medicine Gene Therapy 244

Pharmaceutical Technology

OCTOBER 4, 2022

Shionogi & Co and the United Nations (UN)-backed public health organisation Medicines Patent Pool (MPP) have entered a voluntary licence agreement for the former’s oral Covid-19 antiviral candidate ensitrelvir fumaric acid (S-217622). An investigational Covid-19 drug, ensitrelvir is an inhibitor of 3CL protease.

Licensing 147

Licensing Licensing Manufacturing Medicine 147

Pharmaceutical Technology

JULY 28, 2022

The collaboration comes after Cidara filed a New Drug Application (NDA) for rezafungin to treat candidemia and invasive candidiasis. Rezafungin for injection received Qualified Infectious Disease Product (QIDP) designation from the US Food and Drug Administration (FDA) earlier, which gives the NDA priority review. “By

Licensing 147

Licensing Licensing Clinical Trials Clinical Trials 147

Bio Pharma Dive

JUNE 18, 2024

With a drug licensed from Novartis, the new biotech startup aims to reduce the ‘remnant’ cholesterol it says existing medicines can’t address.

Licensing 173

Licensing Licensing Medicine Drugs 173

Outsourcing Pharma

SEPTEMBER 14, 2023

Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firmâs small molecule cancer treatment.

Medicine 93

Medicine Licensing Licensing Drugs 93

Pharmaceutical Technology

JANUARY 23, 2023

“We look forward to utilising our development and commercial capabilities to expand the potential of this innovative medicine to patients beyond China. “We We have a strong track record of working with companies that share our focus on bringing transformative medicines to patients around the globe who need them.”

Licensing 130

Licensing Licensing Sales Medicine 130

Bio Pharma Dive

DECEMBER 18, 2024

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.

Licensing 154

Licensing Licensing Medicine Development 154

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 23, 2023

With the chemists and druggists across the country opposing the sale of drugs through online, the Central government is taking a stand that the sale of medicines should be strictly under the provisions of the existing regulations and the State Licensing Authorities (SLAs) are legally empowered to act against violation of the legal provisions.

Pharmacy 188

Pharmacy Sales Licensing Licensing 188

XTalks

DECEMBER 4, 2024

The company has secured Orphan Drug designations for Friedreich’s ataxia, offering benefits like market exclusivity and eligibility for Priority Review vouchers. These efforts aim to fast-track commercialization and out-licensing agreements in one of the world’s most promising pharmaceutical markets.

Bioavailability 111

Bioavailability Genetic Disease Marketing RNA 111

Pharmaceutical Technology

OCTOBER 7, 2022

Provention Bio and Sanofi US have signed a co-promotion agreement to launch the former’s lead investigational drug candidate, teplizumab for the delay in the onset of clinical type 1 diabetes (T1D). The US Food and Drug Administration (FDA) is presently reviewing teplizumab for the delay of clinical T1D in people who are at risk.

FDA Approval 299

FDA Approval Licensing Licensing Antibody 299

Pharmaceutical Technology

JUNE 19, 2023

Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar. It plans to seek regulatory approval from the European Medicines Agency, the China National Medical Products Administration and the US Food and Drug Administration.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

STAT News

OCTOBER 20, 2022

Amid a push to widen access to medicines to poor countries, Novartis has reached an agreement to license one of its best-selling cancer treatments so that generic manufacturers can produce copies for distribution to 44 low- and middle-income nations. Continue to STAT+ to read the full story…

Licensing 98

Licensing Licensing Medicine Manufacturing 98

Pharmaceutical Technology

APRIL 6, 2023

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted ADvantage Therapeutics’ immunotherapy AD04 an Innovation Passport for the treatment of Alzheimer’s disease. The difficulty in finding a treatment for Alzheimer’s disease has plagued the drug industry for decades.

FDA Approval 264

FDA Approval Licensing Licensing Antibody 264

Pharmaceutical Technology

DECEMBER 27, 2022

Indian pharmaceutical company Hetero has received the World Health Organization Prequalification of Medicines Program (WHO PQ) approval for its Nirmacom (nirmatrelvir). The company stated that Nirmacom is a generic version of Pfizer ’s Covid-19 oral antiviral drug, Paxlovid, a SARS-CoV-2 main protease (Mpro) inhibitor.

Licensing 195

Licensing Licensing Containment Medicine 195

Pharmaceutical Technology

APRIL 27, 2023

The European Commission’s (EC) long-anticipated pharma reform plans in the European Union have finally been unveiled , indicating a focus on improving access to medicines across the bloc while cutting down on market exclusivity. Outside of these steps, the reform targets drug shortages and pharma industry’s environmental impact.

Marketing 264

Marketing Medicine Production Clinical Trials 264

Bio Pharma Dive

MAY 30, 2023

The biotech, which went public in 2021 to develop a cancer drug licensed from Daiichi Sankyo, may try to acquire a different tumor-targeting medicine to grow its pipeline.

Licensing 143

Licensing Licensing Medicine Development 143

pharmaphorum

MARCH 24, 2022

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. The post GSK partners LifeMine on fungi-derived medicines appeared first on.

Medicine 105

Medicine Genomics Genome Engineer 105

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). Till date, the company has signed a total of 12 ADC licensing deals, worth more than $5bn.

Antibody 130

Antibody Development Drugs Licensing 130

Pharmaceutical Technology

AUGUST 25, 2022

BioMarin chairman and CEO Jean-Jacques Bienaimé said: “Roctavian approval in Europe is a historic milestone in medicine and is built upon almost four decades of scientific discovery, innovation and perseverance. “We The company plans to resubmit a Biologics License Application (BLA) for Roctavian by the end of next month.

Gene Therapy 264

Gene Therapy Gene Clinical Trials Clinical Trials 264

STAT News

DECEMBER 21, 2022

California authorities are seeking to revoke a license held by a CVS Health mail-order pharmacy unit for violating several state laws that govern shipments of various controlled substances — including prescription painkillers and ADHD medicines — directly to patients. Continue to STAT+ to read the full story…

Licensing 105

Licensing Licensing Pharmacy Medicine 105

pharmaphorum

MAY 4, 2022

Testing drug compounds on a chip designed to mimic human organs sounds closer to science fiction than reality, yet the technology already exists and is already being put to use. The limits of animal models in drug discovery are well known. The limits of animal models in drug discovery are well known. Beyond testing.

Drugs 143

Drugs Licensing Licensing Pharma Companies 143

Pharmaceutical Technology

MARCH 31, 2023

On March 30, ViiV Healthcare and Medicines Patent Pool (MPP), announced sublicensing agreements with the pharma manufacturers Aurobindo , Cipla and Viatris to produce generic forms of the long-acting cabotegravir used as pre-exposure prophylaxis (PrEP) for HIV. This includes Apretude and the two oral drugs— Descovy and Truvada.

Medicine 130

Medicine Manufacturing Pharma Companies Licensing 130

Pharmaceutical Technology

AUGUST 8, 2022

AstraZeneca and Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) has received expanded approval from the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.

FDA Approval 264

FDA Approval HR Clinical Trials Clinical Trials 264

Drug Patent Watch

OCTOBER 12, 2021

Imtiaz Hasan et al in Journal of Biosciences and Medicines under a Creative Commons Attribution 4.0 International License Abstract Development of generic drug product…. This paper was originally published by Md.

Generic Drugs 105

Generic Drugs Production Development Drugs 105